NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer diagnostic testing services, saw its stock surge 5.2% in pre-market trading Wednesday after reporting strong fourth-quarter and full-year 2024 financial results.
The company's Q4 revenue reached $172 million, marking the ninth consecutive quarter of double-digit growth. Clinical testing volumes increased by 9% year-over-year, while revenue per test rose by 5%. Notably, NeoGenomics achieved an adjusted gross margin of 48%, the highest in 20 quarters, driven by revenue growth and operational leverage.
A significant highlight was the 24% growth in next-generation sequencing (NGS) revenue for the quarter and 34% for the full year. NGS now represents over 30% of NeoGenomics' total revenue, reflecting the company's strategic focus on this high-growth segment.
NeoGenomics' adjusted EBITDA improved by 27% for the quarter, marking the sixth consecutive quarter of positive adjusted EBITDA. The company served nearly 700,000 patients in 2024, positioning itself well to achieve its goal of serving 1 million patients annually by 2028.
For the full year 2024, NeoGenomics reported revenue of $661 million, up 12% from the prior year. Adjusted gross margin improved by 245 basis points to 47%, and cash flow from operations was positive at $7 million, a significant improvement of 460% from the previous year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.